Treating difficult-to-treat psychosis: Comments on Siskind et al. (2018)
Author(s)
Lal, Sweta
Suetani, Shuichi
Pant, Milind
Parker, Stephen
Year published
2018
Metadata
Show full item recordAbstract
To the Editor
Despite clozapine being the pharmacological agent of choice in treatment-resistant schizophrenia (Galletly et al., 2016), approximately 60% of patients trialled on this medication will have suboptimal clinical response (Siskind et al., 2018). The systematic review by Siskind et al. (2018) addresses the important question of clozapine augmentation strategies and was thorough in its consideration of both pharmacological and non-pharmacological interventions. The consideration of augmentation strategies was broad including electroconvulsive therapy and cognitive behaviour therapy, in addition to nutraceuticals and ...
View more >To the Editor Despite clozapine being the pharmacological agent of choice in treatment-resistant schizophrenia (Galletly et al., 2016), approximately 60% of patients trialled on this medication will have suboptimal clinical response (Siskind et al., 2018). The systematic review by Siskind et al. (2018) addresses the important question of clozapine augmentation strategies and was thorough in its consideration of both pharmacological and non-pharmacological interventions. The consideration of augmentation strategies was broad including electroconvulsive therapy and cognitive behaviour therapy, in addition to nutraceuticals and more novel pharmacological agents such as Ginkgo Biloba, memantine and minocycline. Their review comprehensively summarises the current evidence base and is of relevance to clinicians where augmentation is commonly trialled in the absence of clear guidance.
View less >
View more >To the Editor Despite clozapine being the pharmacological agent of choice in treatment-resistant schizophrenia (Galletly et al., 2016), approximately 60% of patients trialled on this medication will have suboptimal clinical response (Siskind et al., 2018). The systematic review by Siskind et al. (2018) addresses the important question of clozapine augmentation strategies and was thorough in its consideration of both pharmacological and non-pharmacological interventions. The consideration of augmentation strategies was broad including electroconvulsive therapy and cognitive behaviour therapy, in addition to nutraceuticals and more novel pharmacological agents such as Ginkgo Biloba, memantine and minocycline. Their review comprehensively summarises the current evidence base and is of relevance to clinicians where augmentation is commonly trialled in the absence of clear guidance.
View less >
Journal Title
Australian and New Zealand Journal of Psychiatry
Volume
52
Issue
12
Subject
Biomedical and clinical sciences
Clinical sciences
Psychology
Science & Technology
Life Sciences & Biomedicine
Psychiatry
SCHIZOPHRENIA
Science & Technology